SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of competing RRP treatment Voceryq has put Precigens PAPZIMEOS in focus, with traders debating whether the new entrant will erode its sales. Bears see a direct competitive threat, while bulls point to PAPZIMEOS full approval and commercial head start and question Inovios ability to commercialize an accelerated-approval drug.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Discussion centers on Compounds institutional-market launch and treasury-backed institutional finance push, which traders view as a potential catalyst alongside the protocols planned upgrades. Optimism about COMPs limited supply and a possible breakout is tempered by complaints that it continues to lag other crypto assets.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 report and stronger-than-expected Q4 profit outlook are driving attention, with shares rising despite revenue and EPS misses. Traders are focused on subscriber growth and improved margins, while some question the rally given the earnings shortfall and higher expenses.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios shares sold off despite a quarterly earnings beat as its outlook signaled slower organic growth, prompting concerns about deceleration and softer guidance. Traders are split between viewing the drop as an overreaction and buy-the-dip opportunity, and seeing the slower outlook as outweighing the results; some remain positive on Twilios longer-term AI communications potential.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is drawing attention amid a broad selloff in Chinese equities, with traders citing the CSI 300s bear-market decline, weak domestic demand and added uncertainty around AI export restrictions. The community is divided between warnings of a prolonged downturn and views that beaten-down China shares may be nearing a base.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Attention is centered on Zebecs payroll and payments integrations, particularly the MoneyGram/Stellar connection and a reported Germany/AllUnity deployment, which bullish traders view as adoption catalysts. Skeptics counter that partnership news has yet to translate into sustained token demand or price strength, while speculation about additional Robinhood or Ripple links remains unconfirmed.

OpenAI

OpenAIs potential IPO is driving attention, with traders debating reports that the listing could slip to 2027 amid market volatility and heightened safety and legal scrutiny. The discussion is split between enthusiasm for a major AI listing and skepticism about OpenAIs valuation, cash burn, and ability to sustain growth against competitors.

Artificial Superintelligence Alliance (FET) is a cryptocurrency launched in 2018. Artificial Superintelligence Alliance has a current supply of 2,714,384,546.672 with 2,419,135,848.3909366 in circulation. The last known price of Artificial Superintelligence Alliance is 0.16707757 USD and is up 1.84 over the last 24 hours. It is currently trading on 592 active market(s) with $193,186,396.23 traded over the last 24 hours. More information can be found at https://superintelligence.io/.

Fetch.ai

FETs price action and its place in the AI-crypto trade dominate the discussion, with traders watching for a breakout and describing relative strength during broader market weakness. Bullish dip-buying and accumulation hopes coexist with frustration over lagging performance and concern that Bitcoin weakness could weigh on the token.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of whether the S&P 500 rally is broadening beyond mega-cap tech, with traders highlighting its relative strength and recent highs as evidence of rotation into the average stock. Others warn that participation remains uneven and question whether the rotation can persist, especially as technology leadership shifts.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The Crocs Brand segment refers to the United States, South Korea, China, Japan, Singapore, Canada, Germany, Great Britain, France, Malaysia, Australia, Puerto Rico, the Netherlands, Australia, India, and Ireland. The HEYDUDE Brand segment focuses on the United States. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs is drawing attention after quarterly results topped expectations and management raised its outlook, citing a continuing HEYDUDE recovery and steady demand for its core brand; the news fueled a sharp rally. Traders are cheering the breakout, while others warn of profit-taking and point to continued weakness in North American sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Organon (OGN) Q3 Earnings and Revenues Top Estimates

Organon (OGN) delivered earnings and revenue surprises of +3.30% and +0.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Organon Announces Quarterly Dividend

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the companys Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock...

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (SEC). The...

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Womens Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA, a hormone-free, copper intrauterine...

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Organon to Present New Real-World Analysis of VTAMA (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new real-world analysis of patients with atopic dermatitis (AD) treated with VTAMA (tapinarof) cream, 1% will be on display at the 2026 Fall...

Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA, a Hormone-Free Intrauterine Device

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the US Food and Drug Administration (FDA) has accepted for review Sebela Womens Healths supplemental New Drug Application (sNDA) for MIUDELLA...

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Pharmaceutical giants are aggressively pursuing acquisitions to offset looming patent cliffs, as major blockbuster drugs face loss of exclusivity over the next several years.</li><li>Firms are trying to add new drugs to their portfolio with their deals, expanding into new or supplementing existing therapeutic areas.&nbsp;</li><li>Average deal size has climbed to $527.3 million in 2026, up from $365 million in 2025, CNBC reported.</li></ul>Global biopharma mergers and acquisitions have accelerated sharply in 2026, with deal value reportedly reaching $106 billion across 201 transactions through early June.If the current pace continues, the sector is projected to exceed $250 billion in total deal value for the full year—the strongest performance since the 2019 pre-pandemic peak, CNBC <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/06/04/biotech-ma-dealmaking-pharma-106-billion.html">reported</a>, citing PitchBook data.Pharmaceutical giants are aggressively pursuing acquisitions to offset looming patent expiries, as major blockbuster drugs face loss of exclusivity over the next several years. Firms are trying to add new drugs to their portfolio with their deals, expanding into new or supplementing existing therapeutic areas.“Pharma companies [are] really buying stuff like it’s going out of fashion,” Rajesh Kumar, head of life sciences and healthcare equity research at HSBC, told CNBC.Activity has shifted heavily toward strategic “bolt-on” acquisitions in the $1 billion to $5 billion range rather than large leveraged buyouts or mega-mergers, Nanna Lüneborg, general partner at life sciences venture capital firm Forbion, told CNBC. She doesn’t believe pharma is panic buying, but noted that many companies are prioritizing products that are close to commercialization while also investing in earlier-stage assets to gain access to innovative new technologies.Average deal size has climbed to $527.3 million so far in 2026, up from $365 million in 2025, CNBC reported.&nbsp;<h2 class="st-heading-2">Five Biggest Mergers And Acquisitions In US Biopharma Space In 2026</h2>Here are the five largest announced year-to-date:<ul><li>Sun Pharmaceutical Industries acquires Organon: India’s Sun Pharma <a href="https://stocktwits.com/news-articles/markets/equity/ogn-stock-jumps-after-sun-pharma-all-cash-buyout-offer/cZBNaqaRe2f">agreed</a> to buy New Jersey-based Organon in an all-cash deal at $14 per share for an $11.75 billion enterprise value. Organon’s portfolio of more than 70 medicines, including a strong biosimilars and women’s health franchise, gives Sun immediate scale in the U.S., China, and Brazil.</li><li>Gilead Sciences (<a href="https://stocktwits.com/symbol/GILD">GILD</a>) acquires Arcellx: The $7.8 billion deal, <a href="https://stocktwits.com/news-articles/markets/equity/why-did-aclx-stock-surge-in-pre-market-gilead-acquisition/cZRtFxoR4yT">announced</a> in the first quarter and completed on April 28, bolsters Gilead’s oncology and autoimmune pipeline with Arcellx’s next-generation CAR-T cell therapy for multiple myeloma.</li><li>Merck &amp; Co. (<a href="https://stocktwits.com/symbol/MRK">MRK</a>) acquires Terns Pharmaceuticals: Merck purchased the California-based biopharma for $6.7 billion in a deal <a href="https://stocktwits.com/news-articles/markets/equity/merck-to-acquire-terns-signaling-fresh-push-in-competitive-cancer-drug-race/cZ3YnhpRISB">announced</a> in late March. The acquisition centers on Terns' oral drug candidate TERN-701 for chronic myeloid leukemia.</li><li>Eli Lilly (<a href="https://stocktwits.com/symbol/LLY">LLY</a>) acquires Centessa Pharmaceuticals: The $7.8 billion total consideration <a href="https://stocktwits.com/news-articles/markets/equity/cnta-stock-surges-pre-market-what-s-the-eli-lilly-connection/cZEPMWsRIV7">deal</a>, announced in March, targeted Centessa’s pipeline of experimental therapies for the treatment of excessive daytime sleepiness and related neurological conditions.&nbsp;</li><li>Biogen (<a href="https://stocktwits.com/symbol/BIIB">BIIB</a>) acquires Apellis Pharmaceuticals: Biogen gained the Massachusetts-based company’s approved therapies Syfovre and Empaveli, plus additional immunology assets, in a $5.6 billion <a href="https://stocktwits.com/news-articles/markets/equity/apls-stock-soars-after-biogen-acquire-5-6b-deal/cZEPMW3RIVe">deal</a> announced on March 31.</li></ul>The State Street SPDR S&amp;P Biotech ETF (<a href="https://stocktwits.com/symbol/XBI">XBI</a>), which tracks the S&amp;P Biotechnology Select Industry Index, has risen 9% year-to-date, trading near $130.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gm-stock-climbs-as-former-cruise-team-reportedly-returns-to-build-hands-free-consumer-vehicles/cZ0ZZ0PRez5">GM Stock Climbs As Former Cruise Team Reportedly Returns To Build Hands-Free Consumer Vehicles</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.

Arcellx Inc

Apellis Pharmaceuticals Inc

Biogen Inc

Centessa Pharmaceuticals PLC - ADR

Gilead Sciences, Inc.

Lilly(Eli) & Co

Merck & Co Inc

Terns Pharmaceuticals Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.84
Prev Close	$13.81
Open	$13.83
Dividend Yield	4.74%
50-Day Moving Average	$13.74
Beta	0.81
Avg. Volume	2.61M
PE Ratio	17.73

52-Week High	$13.84
52-Week Low	$5.69
Market Capitalization	$3.63B
EPS (Annual)	$0.7171
Price to Book	3.61
Revenue Per Employee	$621,600.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

OGN Fundamentals